Liraglutide Injection
NDC Package 70748-346-02
Package Information
Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitusLimitations of Use: Liraglutide injection contains liraglutide. This formulation utilizes a injection delivery system. Marketed by Lupin Pharmaceuticals, Inc., this product is identified by NDC 70748-346 and is authorized under FDA application ANDA215421.
Identification & Billing
- RxCUI: 897122 - liraglutide 6 MG/ML in 3 ML Pen Injector
- RxCUI: 897122 - 3 ML liraglutide 6 MG/ML Pen Injector
- RxCUI: 897122 - liraglutide 18 MG per 3 ML Pen Injector
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70748 - Lupin Pharmaceuticals, Inc.
- 70748-346 - Liraglutide
- 70748-346-02 - 2 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC
- 70748-346 - Liraglutide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (70748-346). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70748-346-02 identifies a specific commercial package of 2 syringe, plastic in 1 carton / 3 ml in 1 syringe, plastic of Liraglutide, a human prescription drug labeled by Lupin Pharmaceuticals, Inc.. This injection is formulated for subcutaneous use and contains liraglutide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lupin Pharmaceuticals, Inc. on October 02, 2025. The current certification is valid through December 31, 2027.
How is this Lupin Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70748034602. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 6 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.